Two lipid-lowering drugs have been approved by the FDA and cardiologists are wasting no time in prescribing them. Though he cautions the risks of early adoption of drugs approved while outcome trials are ongoing,
Stanley F. Fernandez, MD, PhD, assistant professor in the
division of cardiology, remains impressed with the drugs. These drugs are "very exciting for the cardiology community,” he said. “The degree of LDL lowering seen in this class...is very impressive; and its side effect profile is very reassuring,” said Fernandez.